Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ovarian Cancer Immunotherapy and Personalized Medicine.

Literature DB >> 34207103

Ovarian Cancer Immunotherapy and Personalized Medicine.

Susan Morand¹, Monika Devanaboyina¹, Hannah Staats¹, Laura Stanbery², John Nemunaitis².

Abstract

Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer.

Entities: Chemical Disease Gene Species

Keywords: biomarker; immunotherapy; ovarian cancer

Year: 2021 PMID： 34207103 DOI： 10.3390/ijms22126532

Source DB: PubMed Journal: Int J Mol Sci ISSN： 1422-0067 Impact factor: 5.923

15 in total

1. Potential Diagnostic and Prognostic Values of CBX8 Expression in Liver Hepatocellular Carcinoma, Kidney Renal Clear Cell Carcinoma, and Ovarian Cancer: A Study Based on TCGA Data Mining.

Authors: Jie Lin; Lizhu Chen; Dingjie Wu; Jiexiang Lin; Bin Liu; Ciren Guo
Journal: Comput Math Methods Med Date: 2022-06-29 Impact factor: 2.809

2. Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer.

Authors: Ying Guo; Na Yang; Gang Li; Xiurong Yin; Lixia Dong
Journal: J Immunol Res Date: 2022-05-18 Impact factor: 4.493

Review 3. A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis.

Authors: Xiaolin Qing; Liting Liu; Xiguang Mao
Journal: Comput Math Methods Med Date: 2022-05-25 Impact factor: 2.809

Review 4. Therapeutic Prospects of Polysaccharides for Ovarian Cancer.

Authors: Kaili Wang; Mengcheng Cai; Shuai Sun; Wen Cheng; Dongxia Zhai; Zhexin Ni; Chaoqin Yu
Journal: Front Nutr Date: 2022-04-07

5. Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment.

Authors: Haizhou Ji; Mi Ren; Tongyu Liu; Yang Sun
Journal: Dis Markers Date: 2021-11-19 Impact factor: 3.434

6. Downregulated exosome-associated gene FGF9 as a novel diagnostic and prognostic target for ovarian cancer and its underlying roles in immune regulation.

Authors: Zhijie Xu; Yuan Cai; Wei Liu; Fanhua Kang; Qingchun He; Qianhui Hong; Wenqin Zhang; Jianbo Li; Yuanliang Yan; Jinwu Peng
Journal: Aging (Albany NY) Date: 2022-02-21 Impact factor: 5.682

7. Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis.

Authors: Duygu Ozmadenci; Jayanth S Shankara Narayanan; Jacob Andrew; Marjaana Ojalill; Allison M Barrie; Shulin Jiang; Samhita Iyer; Xiao Lei Chen; Michael Rose; Valeria Estrada; Alfredo Molinolo; Thomas Bertotto; Zbigniew Mikulski; Michael C McHale; Rebekah R White; Denise C Connolly; Jonathan A Pachter; Vijay K Kuchroo; Dwayne G Stupack; David D Schlaepfer
Journal: Proc Natl Acad Sci U S A Date: 2022-04-25 Impact factor: 12.779